(CLBT) Cellebrite DI - Overview
Exchange: NASDAQ •
Country: Israel •
Currency: USD •
Type: Common Stock •
ISIN: IL0011794802
Digital Forensics, Extraction, Analysis, Case Management, Training
Total Rating 50
Risk 93
Buy Signal -0.70
EPS (Earnings per Share)
Revenue
| Risk 5d forecast | |
|---|---|
| Volatility | 41.5% |
| Relative Tail Risk | -12.4% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | -0.78 |
| Alpha | -43.74 |
| Character TTM | |
|---|---|
| Beta | 0.696 |
| Beta Downside | 0.562 |
| Drawdowns 3y | |
|---|---|
| Max DD | 48.00% |
| CAGR/Max DD | 0.90 |
Description: CLBT Cellebrite DI January 11, 2026
Cellebrite DI Ltd. (NASDAQ: CLBT) builds software platforms that enable legally sanctioned investigations across the globe, covering the full forensic lifecycle-from data acquisition and decoding to analysis, visualization, and case management. Its flagship products include Inseyets for evidence collection, Pathfinder for automated analysis, Smart Search for open-source intelligence, and Guardian for evidence management, with enterprise-focused extensions such as Endpoint Inspector and Endpoint Mobile Now.
In FY 2023 the company reported revenue of roughly $210 million, a year-over-year increase of about 15%, and an operating margin near 18%, reflecting strong demand from law-enforcement agencies and corporate security units. The digital-forensics market is expanding at a compound annual growth rate of 12-14% driven by rising cyber-crime incidents, stricter data-privacy regulations, and increasing budgets for investigative technology in both the public and private sectors.
For a deeper quantitative comparison, you might explore ValueRay’s analyst toolkit to benchmark Cellebrite’s performance against peers.
Piotroski VR‑10 (Strict, 0-10) 7.0
| Net Income: 76.3m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.17 > 0.02 and ΔFCF/TA 0.97 > 1.0 |
| NWC/Revenue: 77.10% < 20% (prev 59.33%; Δ 17.76% < -1%) |
| CFO/TA 0.18 > 3% & CFO 152.7m > Net Income 76.3m |
| Net Debt (-259.9m) to EBITDA (77.4m): -3.36 < 3 |
| Current Ratio: 2.11 > 1.5 & < 3 |
| Outstanding Shares: last quarter (249.7m) vs 12m ago 19.65% < -2% |
| Gross Margin: 83.96% > 18% (prev 0.84%; Δ 8312 % > 0.5%) |
| Asset Turnover: 62.30% > 50% (prev 61.21%; Δ 1.09% > 0%) |
| Interest Coverage Ratio: 49.44 > 6 (EBITDA TTM 77.4m / Interest Expense TTM 1.35m) |
Altman Z'' 4.17
| A: 0.42 (Total Current Assets 668.4m - Total Current Liabilities 316.9m) / Total Assets 834.3m |
| B: -0.13 (Retained Earnings -107.8m / Total Assets 834.3m) |
| C: 0.09 (EBIT TTM 66.7m / Avg Total Assets 731.8m) |
| D: 1.16 (Book Value of Equity 447.8m / Total Liabilities 386.6m) |
| Altman-Z'' Score: 4.17 = AA |
Beneish M -3.06
| DSRI: 0.94 (Receivables 104.2m/93.7m, Revenue 455.9m/385.2m) |
| GMI: 1.01 (GM 83.96% / 84.45%) |
| AQI: 0.96 (AQ_t 0.15 / AQ_t-1 0.16) |
| SGI: 1.18 (Revenue 455.9m / 385.2m) |
| TATA: -0.09 (NI 76.3m - CFO 152.7m) / TA 834.3m) |
| Beneish M-Score: -3.06 (Cap -4..+1) = AA |
What is the price of CLBT shares?
As of January 29, 2026, the stock is trading at USD 16.01 with a total of 2,180,539 shares traded.
Over the past week, the price has changed by +1.72%, over one month by -12.23%, over three months by -13.41% and over the past year by -33.76%.
Over the past week, the price has changed by +1.72%, over one month by -12.23%, over three months by -13.41% and over the past year by -33.76%.
Is CLBT a buy, sell or hold?
Cellebrite DI has received a consensus analysts rating of 4.75.
Therefore, it is recommended to buy CLBT.
- StrongBuy: 6
- Buy: 2
- Hold: 0
- Sell: 0
- StrongSell: 0
What are the forecasts/targets for the CLBT price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 24.7 | 54.3% |
| Analysts Target Price | 24.7 | 54.3% |
| ValueRay Target Price | 19.2 | 19.8% |
CLBT Fundamental Data Overview January 25, 2026
P/E Trailing = 41.7632
P/E Forward = 39.6825
P/S = 8.51
P/B = 8.6662
Revenue TTM = 455.9m USD
EBIT TTM = 66.7m USD
EBITDA TTM = 77.4m USD
Long Term Debt = 21.4m USD (from capitalLeaseObligations, last quarter)
Short Term Debt = 3.62m USD (from shortTermDebt, last quarter)
Debt = 21.4m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -259.9m USD (from netDebt column, last quarter)
Enterprise Value = 3.38b USD (3.88b + Debt 21.4m - CCE 525.7m)
Interest Coverage Ratio = 49.44 (Ebit TTM 66.7m / Interest Expense TTM 1.35m)
EV/FCF = 24.26x (Enterprise Value 3.38b / FCF TTM 139.1m)
FCF Yield = 4.12% (FCF TTM 139.1m / Enterprise Value 3.38b)
FCF Margin = 30.51% (FCF TTM 139.1m / Revenue TTM 455.9m)
Net Margin = 16.74% (Net Income TTM 76.3m / Revenue TTM 455.9m)
Gross Margin = 83.96% ((Revenue TTM 455.9m - Cost of Revenue TTM 73.1m) / Revenue TTM)
Gross Margin QoQ = 83.88% (prev 84.39%)
Tobins Q-Ratio = 4.05 (Enterprise Value 3.38b / Total Assets 834.3m)
Interest Expense / Debt = 6.29% (Interest Expense 1.35m / Debt 21.4m)
Taxrate = 16.88% (4.10m / 24.3m)
NOPAT = 55.4m (EBIT 66.7m * (1 - 16.88%))
Current Ratio = 2.11 (Total Current Assets 668.4m / Total Current Liabilities 316.9m)
Debt / Equity = 0.05 (Debt 21.4m / totalStockholderEquity, last quarter 447.7m)
Debt / EBITDA = -3.36 (Net Debt -259.9m / EBITDA 77.4m)
Debt / FCF = -1.87 (Net Debt -259.9m / FCF TTM 139.1m)
Total Stockholder Equity = 388.9m (last 4 quarters mean from totalStockholderEquity)
RoA = 10.43% (Net Income 76.3m / Total Assets 834.3m)
RoE = 19.63% (Net Income TTM 76.3m / Total Stockholder Equity 388.9m)
RoCE = 16.25% (EBIT 66.7m / Capital Employed (Equity 388.9m + L.T.Debt 21.4m))
RoIC = 14.26% (NOPAT 55.4m / Invested Capital 388.9m)
WACC = 8.46% (E(3.88b)/V(3.90b) * Re(8.48%) + D(21.4m)/V(3.90b) * Rd(6.29%) * (1-Tc(0.17)))
Discount Rate = 8.48% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 33.33 | Cagr: 3.53%
[DCF Debug] Terminal Value 79.77% ; FCFF base≈123.0m ; Y1≈151.7m ; Y5≈258.4m
Fair Price DCF = 17.39 (EV 3.99b - Net Debt -259.9m = Equity 4.25b / Shares 244.5m; r=8.46% [WACC]; 5y FCF grow 25.0% → 2.90% )
EPS Correlation: 64.48 | EPS CAGR: 50.80% | SUE: 0.44 | # QB: 0
Revenue Correlation: 97.61 | Revenue CAGR: 17.93% | SUE: 1.10 | # QB: 1
EPS next Quarter (2026-03-31): EPS=0.11 | Chg30d=+0.000 | Revisions Net=-2 | Analysts=6
EPS next Year (2026-12-31): EPS=0.55 | Chg30d=+0.000 | Revisions Net=+7 | Growth EPS=+7.7% | Growth Revenue=+17.2%
P/E Forward = 39.6825
P/S = 8.51
P/B = 8.6662
Revenue TTM = 455.9m USD
EBIT TTM = 66.7m USD
EBITDA TTM = 77.4m USD
Long Term Debt = 21.4m USD (from capitalLeaseObligations, last quarter)
Short Term Debt = 3.62m USD (from shortTermDebt, last quarter)
Debt = 21.4m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -259.9m USD (from netDebt column, last quarter)
Enterprise Value = 3.38b USD (3.88b + Debt 21.4m - CCE 525.7m)
Interest Coverage Ratio = 49.44 (Ebit TTM 66.7m / Interest Expense TTM 1.35m)
EV/FCF = 24.26x (Enterprise Value 3.38b / FCF TTM 139.1m)
FCF Yield = 4.12% (FCF TTM 139.1m / Enterprise Value 3.38b)
FCF Margin = 30.51% (FCF TTM 139.1m / Revenue TTM 455.9m)
Net Margin = 16.74% (Net Income TTM 76.3m / Revenue TTM 455.9m)
Gross Margin = 83.96% ((Revenue TTM 455.9m - Cost of Revenue TTM 73.1m) / Revenue TTM)
Gross Margin QoQ = 83.88% (prev 84.39%)
Tobins Q-Ratio = 4.05 (Enterprise Value 3.38b / Total Assets 834.3m)
Interest Expense / Debt = 6.29% (Interest Expense 1.35m / Debt 21.4m)
Taxrate = 16.88% (4.10m / 24.3m)
NOPAT = 55.4m (EBIT 66.7m * (1 - 16.88%))
Current Ratio = 2.11 (Total Current Assets 668.4m / Total Current Liabilities 316.9m)
Debt / Equity = 0.05 (Debt 21.4m / totalStockholderEquity, last quarter 447.7m)
Debt / EBITDA = -3.36 (Net Debt -259.9m / EBITDA 77.4m)
Debt / FCF = -1.87 (Net Debt -259.9m / FCF TTM 139.1m)
Total Stockholder Equity = 388.9m (last 4 quarters mean from totalStockholderEquity)
RoA = 10.43% (Net Income 76.3m / Total Assets 834.3m)
RoE = 19.63% (Net Income TTM 76.3m / Total Stockholder Equity 388.9m)
RoCE = 16.25% (EBIT 66.7m / Capital Employed (Equity 388.9m + L.T.Debt 21.4m))
RoIC = 14.26% (NOPAT 55.4m / Invested Capital 388.9m)
WACC = 8.46% (E(3.88b)/V(3.90b) * Re(8.48%) + D(21.4m)/V(3.90b) * Rd(6.29%) * (1-Tc(0.17)))
Discount Rate = 8.48% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 33.33 | Cagr: 3.53%
[DCF Debug] Terminal Value 79.77% ; FCFF base≈123.0m ; Y1≈151.7m ; Y5≈258.4m
Fair Price DCF = 17.39 (EV 3.99b - Net Debt -259.9m = Equity 4.25b / Shares 244.5m; r=8.46% [WACC]; 5y FCF grow 25.0% → 2.90% )
EPS Correlation: 64.48 | EPS CAGR: 50.80% | SUE: 0.44 | # QB: 0
Revenue Correlation: 97.61 | Revenue CAGR: 17.93% | SUE: 1.10 | # QB: 1
EPS next Quarter (2026-03-31): EPS=0.11 | Chg30d=+0.000 | Revisions Net=-2 | Analysts=6
EPS next Year (2026-12-31): EPS=0.55 | Chg30d=+0.000 | Revisions Net=+7 | Growth EPS=+7.7% | Growth Revenue=+17.2%